HHS Overrules FDA on Plan B

Despite scientific evidence that Plan B emergency contraception is safe for women of all ages, the department of Health and Human Services declined to approve it for over-the-counter use.

Written byTia Ghose
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, VIXYVIEW

After the department of Health and Human Services (HHS) overruled the Food and Drug Administration (FDA) on Wednesday regarding the approval of emergency contraceptive Plan B, many are wondering whether politics, not science, guided the decision. The department ruled to keep existing restrictions on Plan B, which currently cannot be sold without a prescription to those younger than 17, despite the FDA’s conclusion that the drug was safe and effective for fertile women of all ages and should be available over-the-counter.

As a rationale for keeping the restrictions in place, HHS head Kathleen Sebelius said that about 10 percent of women as young as 11 are physically capable of getting pregnant but may lack the cognitive and behavioral development to use Plan B properly.

But ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies